Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.

Iaci JF, Parry TJ, Huang Z, Finklestein SP, Ren J, Barrile DK, Davenport MD, Wu R, Blight AR, Caggiano AO.

Stroke. 2013 Jul;44(7):1942-50. doi: 10.1161/STROKEAHA.111.000147.

2.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Review.

PMID:
22497693
3.
4.

Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.

Dunn J, Blight A.

Curr Med Res Opin. 2011 Jul;27(7):1415-23. doi: 10.1185/03007995.2011.583229. Review.

PMID:
21595605
5.

Mildronate treatment improves functional recovery following middle cerebral artery occlusion in rats.

Svalbe B, Zvejniece L, Vavers E, Pugovics O, Muceniece R, Liepinsh E, Dambrova M.

Behav Brain Res. 2011 Sep 12;222(1):26-32. doi: 10.1016/j.bbr.2011.03.027.

PMID:
21420440
6.

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.

Limone BL, Sidovar MF, Coleman CI.

Health Qual Life Outcomes. 2013 Jun 26;11:105. doi: 10.1186/1477-7525-11-105.

7.

Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study.

Simpson DM, Goldenberg J, Kasner S, Nash M, Reding MJ, Zweifler RM, Suarez G, Zhao P, Henney HR III, Rabinowicz AL, Carrazana E.

J Rehabil Med. 2015 Nov;47(10):924-31. doi: 10.2340/16501977-2033.

8.

Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat.

Sun HS, Doucette TA, Liu Y, Fang Y, Teves L, Aarts M, Ryan CL, Bernard PB, Lau A, Forder JP, Salter MW, Wang YT, Tasker RA, Tymianski M.

Stroke. 2008 Sep;39(9):2544-53. doi: 10.1161/STROKEAHA.107.506048.

9.

An optimized dosing regimen of cimaglermin (neuregulin 1β3, glial growth factor 2) enhances molecular markers of neuroplasticity and functional recovery after permanent ischemic stroke in rats.

Iaci JF, Parry TJ, Huang Z, Pavlopoulos E, Finklestein SP, Ren J, Caggiano A.

J Neurosci Res. 2016 Mar;94(3):253-65. doi: 10.1002/jnr.23699.

10.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR; MS-F203, MS-F204, and Extension Study Investigators..

Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591.

11.

Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.

Blight AR, Henney HR 3rd, Cohen R.

Ann N Y Acad Sci. 2014 Nov;1329:33-44. doi: 10.1111/nyas.12512. Review.

12.

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.

Clin Ther. 2015 Dec 1;37(12):2780-7. doi: 10.1016/j.clinthera.2015.10.014.

13.

Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.

Lugaresi A.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):295-306. doi: 10.1517/17425255.2015.993315. Review.

PMID:
25510833
14.

Dalfampridine: a new agent for symptomatic management of multiple sclerosis.

McDonald S, Clements JN.

Am J Health Syst Pharm. 2011 Dec 15;68(24):2335-40. doi: 10.2146/ajhp110134. Review. Erratum in: Am J Health Syst Pharm. 2012 Apr 1;69(7):544.

PMID:
22135060
16.

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosis.

Weir S, Torkin R, Henney HR 3rd.

Curr Med Res Opin. 2013 Dec;29(12):1627-36. doi: 10.1185/03007995.2012.749221. Review.

PMID:
23157467
17.

Dimeric fibroblast growth factor-2 enhances functional recovery after focal cerebral ischemia.

Berry D, Ren J, Kwan CP, Sietsma DK, Sasisekharan R, Finklestein SP.

Restor Neurol Neurosci. 2005;23(3-4):251-6.

PMID:
16082081
18.

Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke.

Campbell CA, Barone FC, Benham CD, Hadingham SJ, Harries MH, Harling JD, Hills JM, Lewis VA, Mackay KB, Orlek BS, White RF, Parsons AA, Hunter AJ.

Eur J Pharmacol. 2000 Aug 11;401(3):419-28.

PMID:
10936502
19.

Dalfampridine extended release: in multiple sclerosis.

Chwieduk CM, Keating GM.

CNS Drugs. 2010 Oct;24(10):883-91. doi: 10.2165/11205910-000000000-00000. Review.

PMID:
20839898
20.

Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.

Egeberg MD, Oh CY, Bainbridge JL.

Clin Ther. 2012 Nov;34(11):2185-94. doi: 10.1016/j.clinthera.2012.10.003. Review. Erratum in: Clin Ther. 2013 Jun;35(6):900.

PMID:
23123001

Supplemental Content

Support Center